Management of double-refractory multiple myeloma
Jason P Meadows1, Tomer M Mark
1Department of Internal Medicine, University of Hawaii, 1356 Lusitana St. 7th Floor, Honolulu, HI, 96813, USA, jmeadows@hawaii.edu.
Current Hematologic Malignancy Reports
|August 27, 2013
Summary
New therapies are needed for multiple myeloma (MM) patients who relapse after treatment with bortezomib and lenalidomide. This review covers challenges and new treatments for double-refractory MM (DRMM).
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Novel agents like bortezomib and lenalidomide have significantly improved multiple myeloma (MM) outcomes.
- Patient relapse after treatment with these agents necessitates alternative therapeutic strategies.
- Managing double-refractory MM (DRMM) presents complex challenges due to disease, patient, and treatment factors.
Purpose of the Study:
- To review the unique challenges associated with treating double-refractory multiple myeloma (DRMM).
- To discuss recently FDA-approved therapeutic agents for DRMM.
- To highlight novel drugs currently under clinical investigation for DRMM management.
Main Methods:
- Literature review of challenges in treating refractory multiple myeloma.
- Analysis of recently approved therapies for double-refractory MM.
- Survey of ongoing clinical trials for novel DRMM treatments.
Main Results:
- Treatment of DRMM is complex, requiring consideration of multiple patient and disease-related factors.
- Several new agents have received FDA approval, offering new options for DRMM patients.
- Numerous novel therapies are in clinical development, showing promise for future DRMM management.
Conclusions:
- Effective management of double-refractory multiple myeloma requires addressing significant clinical challenges.
- Recent therapeutic advancements and ongoing research offer hope for improved outcomes in DRMM.
- New treatment paradigms are essential to overcome resistance and improve survival for patients with refractory multiple myeloma.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...